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Objective: We prospectively studied the clinical implication of plasma level of soluble fibrin monomer (FM)-fibrinogen
complex, a recently establishedmolecular marker reflecting thrombin activity, in patients with abdominal aortic aneurysm
(AAA) undergoing elective aortic repair.
Methods: The study included 49 patients who underwent elective aneurysm repair using a gelatin-sealed or nonimpreg-
nated Dacron prosthesis. Plasma level of soluble FM-fibrinogen complex was measured before surgery and on days 1, 3,
5, 7, and 10 postoperatively by latex agglutination assay utilizing monoclonal antibody IF-43. Plasma levels of
thrombin-antithrombin complex (TAT), D-dimer, 2-plasmin inhibitor-plasmin complex (PIC), and fibrinogen were
also evaluated.
Results: The preoperative level of soluble FM-fibrinogen complex showed variation in the degree of hemostatic activation,
with fair correlations with TAT (r  0.509, P < .001), D-dimer (r  0.521, P < .001), and PIC (r  0.579, P < .001).
The patients with greater intraoperative blood loss (> 800 mL) showed a significantly elevated plasma level of soluble
FM-fibrinogen complex preoperatively compared with those with less intraoperative blood loss (P  .009). Its
postoperative fluctuation showed a similar pattern to that of TAT, reflecting the time course of coagulation activity.
Gelatin impregnation of the Dacron vascular graft did not seem to influence the postoperative systemic coagulation
mechanism.
Conclusions:The results indicated that soluble FM-fibrinogen complex appears to be a useful diagnostic molecular marker
to assess the activity of the coagulation system, and that its preoperative level may serve as a potential risk factor for
intraoperative hemorrhagic diathesis in patients undergoing elective AAA repair. ( J Vasc Surg 2005;42:200-5.)Abdominal aortic aneurysm (AAA) induces various de-
grees of hemostatic and fibrinolytic disturbance.1-6 Al-
though AAA is rarely associated with clinically symptomatic
disseminated intravascular coagulopathy (DIC) before sur-
gery,1-3,7-9 molecular markers in the plasma demonstrate
marked activation of coagulation and fibrinolysis in many
cases, often showing improvement during the postopera-
tive course.3-5,7-10 However, the clinical value of measuring
these molecular markers in asymptomatic AAA patients
undergoing elective surgery remains unclear.
During the conversion of fibrinogen to fibrin, throm-
bin mediates the cleavage of a pair of fibrinopeptide A
peptides and produces fibrin monomer (FM), which is then
polymerized to form insoluble fibrin clots. FM molecules,
on the other hand, form soluble complexes with fibrinogen
molecules in the presence of a sufficient concentration of
the latter,11,12 and this complex has been defined as soluble
FM-fibrinogen complex.13
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200Recently, a latex agglutination assay system for its mea-
surement has been established by utilizing a monoclonal
antibody named IF-43, which specifically recognizes solu-
ble FM-fibrinogen complex.13-15 This molecular marker
has been shown to contain a distinct entity reflecting
thrombin activity in patients with a variety of diseases,13,14
and is expected to become a diagnostic tool to gain further
insight into hemostatic and fibrinolytic derangement.13,15
Yet, little information has been provided about its clinical
implication, because it has not been studied in a series of
patients with a specific thrombotic disorder.
In the present study, we examined the plasma level of
soluble FM-fibrinogen complex in patients with asymp-
tomatic infrarenal AAA undergoing elective aortic repair to
characterize its clinical significance. We also investigated
the postoperative change of soluble FM-fibrinogen com-
plex in these patients compared with conventional hemo-
static and fibrinolytic markers.
MATERIALS
Patients. Fifty-three consecutive patients underwent
elective repair of infrarenal AAA at the University of Tokyo
Hospital Department of Surgery between December 2002
and June 2004. Two patients with chronic renal failure on
maintenance hemodialysis and another two patients who
received anticoagulant therapy preoperatively were ex-
cluded from the study, because the influence of dialysis and
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remains unclear; 49 patients (44 men and 5 women) were
prospectively studied. Written informed consent was ob-
tained from each subject, and the protocol conformed to
the guideline of the institutional ethics committee.
The clinical characteristics of the patients are summa-
rized in Table I. Patients were assumed to have hyperten-
sion or diabetes mellitus if they were on corresponding
medication. Peripheral vascular disease was diagnosed by
physical examination and cerebrovascular disease from a
medical history of stroke or transient cerebral ischemia. The
diagnosis of coronary artery disease was confirmed by cor-
onary angiography, which was performed preoperatively in
all of the patients included in the study.
Twenty-six patients had had antiplatelet treatment be-
fore surgery. All patients underwent aortic replacement
with a Dacron (DuPont, Wilmington, Del) prosthesis un-
der general anesthesia; a nonimpregnated woven Dacron
graft (Woven Double Velour Vascular Graft, Boston Scien-
tific Medi-tech, Wayne, NJ) was implanted in 16 patients
between December 2002 and September 2003, and a
gelatin-sealed knittedDacron graft (Gelsoft Plus, Vascutek,
Inchinnan, Scotland) was implanted in 33 patients between
August 2003 and June 2004. A 2,000 U bolus of unfrac-
tionated heparin was intravenously administered immedi-
ately before aortic clamping.
The maximum thickness of intraluminal thrombus in
AAA and the anteroposterior diameter of the aneurysm
were preoperatively measured by computed tomography.
Blood samples were obtained in the morning before sur-
gery and on days 1, 3, 5, 7, and 10 postoperatively by
venipuncture from the cubital vein with a standard blood
drawing technique. The samples were collected into tubes
containing 3.13% sodium citrate solution, and centrifuged
for 30 minutes at 3000 rpm and 22° C. The plasma was
separated and kept frozen at70° C until use. Assays were
performed after the plasma samples were thawed in a water
bath at 37° C for at least 30 minutes to assure the temper-
ature of the samples was at 37° C.
Analysis of molecular markers. The plasma level of
soluble FM-fibrinogen complex was determined with a
Table I. Clinical and operative characteristics of the
patients
Age (yrs) 74  7
Sex (male/female) 44/5
Comorbidity (n)
Hypertension 37
Peripheral vascular disease 7
Coronary artery disease 24
Cerebrovascular disease 4
Diabetes mellitus 3
Aneurysmal involvement of iliac arteries 25
Morphologic profiles of aneurysms
Maximum thickness of intraluminal thrombus
(mm)
18.8  8.2
Largest diameter (mm) 60.1  11.4latex agglutination assay kit that uses the monoclonal anti-body IF-43 (Iatro SF, Mitsubishi Kagaku Iatron, Tokyo,
Japan) as described previously.13,14 Thrombin-antithrom-
bin complex (TAT) was measured by time-resolved fluo-
rescence immunoassay kit (LPIA-F TAT, Mitsubishi Ka-
gaku Iatron). The values of D-dimer and 2-plasmin
inhibitor-plasmin complex (PIC) were determined with
latex agglutination assay kits (LPIA ACE D-Dimer and
LPIA ACE PPI, respectively, both fromMitsubishi Kagaku
Iatron). All of these assays were performed on an automatic
analyzer LPIA-A700 (Mitsubishi Kagaku Iatron). Fibrino-
gen was measured by the thrombin time method of Clauss
(CA-1500 and Coagrex-800, both from Sysmex, Hyogo,
Japan). The normal range for each molecular marker deter-
mined by the manufacturer was soluble FM-fibrinogen
complex,7 g/mL; TAT,3.5 ng/mL; D-dimer,1.0
g/mL; PIC, 0.8 g/mL; fibrinogen, 160 to 350
mg/dL.
Statistical analysis. Data are presented as mean SD.
The Student’s t test was used for comparisons between
groups of patients, and relationships between categoric
variables were compared with 2 test. Correlation analyses
were performed using the Pearson’s correlation test. P 
.05 was regarded as statistically significant.
RESULTS
Operative and postoperative profiles of patients.
No patient had clinically overt DIC preoperatively. Tube
graft repair was performed in 19 patients, and bifurcated
graft repair in 30 patients. Two patients underwent con-
comitant additional vascular reconstruction with another
graft (repair of internal iliac artery aneurysm, one; femoro-
popliteal bypass, one). Graft occlusion did not occur. No
patient died30 days postoperatively. Postoperative intra-
abdominal hemorrhage occurred in one patient, who un-
derwent relaparotomy for hemostasis on the same day as
tube graft repair. One patient, who had undergone con-
comitant femoropopliteal bypass grafting, had a cerebral
infarction on day 3 and argatroban was administered for 7
days thereafter. This was the only clinically symptomatic
thrombotic episode in the patients included in the study.
Postoperative anticoagulant therapy was not given in other
patients.
Preoperative levels of soluble FM-fibrinogen com-
plex and other molecular markers. Preoperative plasma
levels of soluble FM-fibrinogen complex, TAT, D-dimer,
and PIC tended to be elevated in AAA patients compared
with the normal ranges (mean, 19.2  16.8 g/mL, 11.5
 11.3 ng/mL, 8.5  6.7 g/mL, and 2.00  1.59
g/mL, respectively). The preoperative levels of fibrino-
gen were150mg/dL in all of the patients, with amean of
336  85 mg/ml. The level of soluble FM-fibrinogen
complex was significantly higher in patients with diabetes
mellitus, although only three patients in the present series
were associated with the disease. The level did not differ
significantly between patients with and without other co-
morbid conditions or associated iliac aneurysm, although
the level in patients with peripheral vascular disease or iliac
aneurysm tended to be elevated. No significant difference
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antiplatelet therapy and those who were not (Table II).
The level did not correlate with age (r  0.185, P 
.204), maximum thickness of intraluminal thrombus in the
aneurysm (r 0.233, P .125), or diameter of AAA (r
0.128, P  .381). The preoperative levels of TAT, D-
dimer, and PIC did not show a correlation with these two
morphologic parameters of the aneurysm, either. On the
other hand, the preoperative level of soluble FM-fibrinogen
complex showed a significant correlation with the levels of
TAT (r  0.509, P  .001), D-dimer (r  0.521, P 
.001), and PIC (r  0.579, P  .001).
Preoperative levels of molecular markers and intra-
operative blood loss. The relationship between the pre-
operative condition and the volume of blood loss during
surgery was evaluated. Two patients who underwent con-
comitant additional vascular reconstruction were excluded
from the following analysis. We divided the patients into
two groups according to the intraoperative blood loss, with
a cutoff of 800 mL, because blood loss 800 mL can
usually be compensated by crystalloid infusion or autolo-
gous transfusion, whereas blood loss  800 mL often
necessitates allogenic transfusion.
Blood loss  800 mL was more frequently observed
in patients who underwent implantation of a bifurcated
graft compared with those treated with a tube graft (P 
.0001), but the amount of blood loss did not seem to be
influenced by gelatin coating of the implanted prosthesis (P
 .261). Blood loss tended to be greater with greater
maximum thickness of intraluminal thrombus (15.5  6.0
vs 20.1  8.8 mm, P  .071) and greater diameter of the
aneurysm (56.2  7.5 vs 62.8  12.9 mm, P  .056).
The preoperative levels of soluble FM-fibrinogen com-
plex, as well as D-dimer and PIC, were higher in patients
who lost 800 mL of blood during the operation, while
preoperative levels of TAT and fibrinogen did not differ
significantly between the two groups (Table III). On the
other hand, the preoperative level of soluble FM-fibrinogen
complex did not differ significantly between patients
treated with a tube graft and those treated with a bifurcated
graft (14.6  16.9 vs 22.1  15.9 g/ml, P  .129).
Postoperative changes of soluble FM-fibrinogen
complex and other molecular markers. The postopera-
Table II. Preoperative level of soluble FM-fibrinogen
complex (g/mL) and preoperative comorbid conditions
or antiplatelet medication
Present Absent P
Hypertention 19.3  17.3 18.8  15.7 .922
Peripheral vascular disease 28.2  21.3 17.7  15.7 .128
Coronary artery disease 21.3  16.9 17.2  16.9 .403
Cerebrovascular disease 17.3  17.4 19.4  16.9 .815
Diabetes mellitus 40.1  7.2 17.9  16.3 .025
Iliac aneurysm 22.6  17.1 15.7  16.0 .148
Antiplatelet medication 21.1  16.2 17.1  17.5 .421tive fluctuations of soluble FM-fibrinogen complex andother molecular markers are shown in the Fig. Two patients
who underwent concomitant additional vascular surgery
were not included in the analysis to exclude the influences
of the additional surgical stress and anticoagulant agents on
the levels of molecular markers.
The patients were divided into two groups according to
the prostheses used (nonimpregnated or gelatin-sealed Da-
cron), so as to assess the effect of gelatin impregnation on
the coagulation system. The plasma level of soluble FM-
fibrinogen complex increased on day 1 postoperatively,
then gradually decreased and reached a plateau (Fig A).
The level of TAT demonstrated a similar course with a
maximum on day 1, but the change was less marked com-
pared with that of soluble FM-fibrinogen complex (Fig B).
The level of D-dimer increased slightly with a small peak on
day 1, decreased on day 3, and increased again with another
peak on day 7 (Fig C). The level of PIC increased gradually
after the operation, reaching the maximum on day 5, and
decreased thereafter (Fig D). All of the molecular markers
still remained above the normal range even on day 10.
The four molecular markers did not show any signifi-
cant differences pre- and postoperatively between patients
treated with a nonimpregnated Dacron prosthesis and
those treated with a gelatin-sealed Dacron graft. Further-
more, the postoperative levels of soluble FM-fibrinogen
complex and fibrinogen did not differ significantly between
patients with intraoperative blood loss  800 mL and
those with less blood loss.
DISCUSSION
The present study examined the clinical characteristics
of the plasma level of soluble FM-fibrinogen complex in
patients undergoing elective repair of an asymptomatic
AAA. The preoperative levels varied widely, and the results
indicated their possible usefulness as a predictive risk factor
for increased intraoperative blood loss. The postoperative
fluctuation showed a similar pattern to that of TAT, indi-
cating the time course of coagulation activity.
Several molecular markers have been established to eval-
uate the status of thrombin generation and its activity.16-18
While the amount of thrombin formation is reflected by
parameters such as prothrombin fragment 1.2 and TAT, the
Table III. Preoperative molecular markers and blood
loss during surgery
Blood loss (mL)
P800  800
Soluble FM-fibrinogen
complex (g/ml)
11.2  12.4 23.8  17.1 .009
TAT (ng/mL) 8.5  9.1 13.4  12.4 .153
D-dimer (g/mL) 6.0  3.8 10.0  7.8 .049
PIC (g/mL) 1.32  0.53 2.19  1.49 .021
Fibrinogen (mg/dL) 334  83 340  90 .794
TAT, Thrombin-antithrombin complex; PIC, 2-plasmin-inhibitor plasmin
complexactual thrombin activity can be inferred from its action on
tions
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tides from a fibrinogen molecule and yields one molecule of
FM. Subsequently, FM molecules are polymerized to form
insoluble fibrin clots. When a sufficient amount of fibrinogen
is present, FM molecules also bind with fibrinogen and form
soluble FM-fibrinogen complex.11,12 Thrombin activity can
be assessed by evaluating the amount of these by-products
yielded through its catalysis.
The usefulness of measurement of fibrinopeptide A has
been demonstrated by previous studies,18-20 and it has
been shown to have a unique profile contrasting with those
of prothrombin fragment 1.2 and TAT.19 However, fibri-
nopeptide A has a very short half-life in plasma and a rapid
assay system for it has not yet been established, limiting the
broad clinical application of its measurement.
Several assays have been developed to measure the level
of FM in plasma.13,21,22 However, some of them also react
with plasmic degradation products that share many struc-
tural features with FM, so the values measured with these
assays reflect the combined actions of thrombin and plas-
min.15 It has been demonstrated that the monoclonal
antibody IF-43 specifically reacts with FM complexed with
fibrinogen molecules and shows no appreciable crossreac-
tivity with fibrinogen or plasmic degradation products.13-15
Postoperative changes of soluble fibrin monomer (FM)-fi
FM-fibrinogen complex. (B) Thrombin-antithrombin
plasmin complex (PIC).  Patients treated with a no
gelatin-sealed Dacron graft. Bars indicate standard deviaThus, the measurement of soluble FM-fibrinogen complexwith IF-43 is considered to reflect thrombin activity distin-
guishably from plasmin activity. Indeed, the plasma con-
centration of soluble FM-fibrinogen complex evaluated
with IF-43 in patients with various underlying conditions
showed distinct properties from those of D-dimer and
TAT.13,14
Local fibrinogen deposition and subsequent thrombus
formation occur continuously in the aneurysm sac, fol-
lowed by concurrent fibrinolysis at the locus.23-25 In most
cases, a dynamic equilibrium is maintained between coag-
ulation and fibrinolysis. In the present series, various de-
grees of compensation maintained between coagulation
and fibrinolysis were reflected by the preoperative level of
soluble FM-fibrinogen complex, which varied broadly from
0.60 to 64.08 g/mL.
The factors determining the level of coagulation activ-
ity in patients with AAA remain unclear. Close relationships
between hemostatic markers in AAA patients and morpho-
logic factors such as the thickness of intraluminal throm-
bus, diameter or volume of the aneurysm, and presence
of associated iliac aneurysms have been previously re-
ported.3,4,26 In the present study, we did not find a signif-
icant correlation between molecular markers, including
soluble FM-fibrinogen complex, and these morphologic
gen complex and other molecular markers. (A) Soluble
lex (TAT). (C) D-dimer. (D) 2-Plasmin inhibitor-
regnated Dacron prosthesis. ● Patients treated with a
.brino
comp
nimpfindings, although patients with an associated iliac aneu-
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ogen complex.
Our result contradicting the previous reports might be
attributable to the limitations of statistical analysis because
of the small sample size. However, our findings could
suggest that the hemostatic activity associated with local
thrombus turnover in the aneurysm sac is influenced by
various factors that are difficult to infer from the structural
profile of the aneurysm.
Several studies have documented the usefulness of he-
mostatic markers in patients with ruptured AAA,6,27 but
little is known about the clinical value of the measurement
of hemostatic and fibrinolytic parameters in asymptomatic
AAA patients undergoing elective aneurysm repair. The
present study showed that patients with greater intraoper-
ative blood loss demonstrated significantly elevated preop-
erative levels of soluble FM-fibrinogen complex, D-dimer,
and PIC. Interestingly, the patient who underwent re-
laparotomy on the same day as tube graft repair because of
postoperative intra-abdominal hemorrhage showed a
markedly elevated plasma level of soluble FM-fibrinogen
complex preoperatively (64.08 g/mL), which was the
highest value among the data collected during the study
period. This may seem paradoxical, because elevated
thrombin activity, reflected by a high plasma level of soluble
FM-fibrinogen complex, is likely to lead to reduced intra-
operative blood loss.
Taking into account the significant correlation between
preoperative levels of soluble FM-fibrinogen complex and
PIC, the present observation could possibly be explained by
the assumption that fibrinolysis is strongly induced in AAA
patients whose coagulation system is already highly acti-
vated and that hemostatic thrombi that form in impaired
vessels during the operation may prematurely resolve be-
cause of plasmin activity before they achieve functional
coagulation. Hypercoagulability associated with concur-
rent fibrinolysis may be one of the causes leading to greater
blood loss during AAA repair.
In the present study, the preoperative level of soluble
FM-fibrinogen complex did not differ significantly between
patients with and without associated iliac aneurysms, and
between patients treated with a tube graft and those treated
with a bifurcated graft. These findings indicated that the
preoperative level of soluble FM-fibrinogen complex, as
well as those of D-dimer and PIC, may reflect a subclinical
hemorrhagic diathesis in patients with AAA, and could
possibly be a useful diagnostic parameter to predict the risk
of increased blood loss during the operation, even in pa-
tients with no clinical manifestation of coagulopathy before
surgery.
On the other hand, the preoperative levels of soluble
FM-fibrinogen complex and TAT showed a fair correlation,
whereas the latter did not demonstrate an association with
intraoperative blood loss. This discrepancy might be attrib-
utable to the different entities of the two molecular mark-
ers, although it could possibly be due to the limitations of
statistical analysis because of the small sample size.The postoperative changes of soluble FM-fibrinogen
complex showed a similar pattern compared with the
course after nonvascular abdominal surgery reported in a
previous study.13 The plasma level reached a peak on day 1
postoperatively, which can be attributed to activated coag-
ulation in response to surgical stress and contact between
the prosthesis and blood flow,4,10 and then gradually de-
creased, reaching a plateau. The postoperative pattern of
TAT paralleled that of soluble FM-fibrinogen complex,
reaching a maximum on day 1, followed by a gradual
decrease thereafter. Nakahara et al13 demonstrated that the
peak of TAT precedes that of soluble FM-fibrinogen com-
plex in the postoperative course of nonvascular abdominal
surgery, since the former represents thrombin generation
and the latter the subsequent thrombin activity. Our data
did not show a difference in the sequential patterns of the
twomolecular markers, probably because the 2-day interval
of blood sampling was not adequate to distinguish between
the two.
The change of PIC indicated gradual activation of fibri-
nolysis, reaching a maximum on day 5. D-dimer demon-
strated two peaks in the postoperative course, on days 1 and 7.
The formation of D-dimer must be preceded by a series of
molecular interactions, including thrombin-mediated fibrin
clot formation, activation of plasminogen by plasminogen
activators, and subsequent fibrin digestion by activated plas-
min. Judging from the changes of thrombin and plasmin
activity, the first peak of D-dimer can probably be attributed
to an increase of fibrin degradation in response to activation of
the coagulation system, and the second peak is likely to be due
to activation of the plasmin cascade.4
Gelatin-coated knitted Dacron grafts have been widely
used in vascular reconstructive surgery because of their easy
handling, low porosity that obviates the need for preclot-
ting, and good healing characteristics.28-30 The impreg-
nated gelatin disappears during the first 10 days after im-
plantation,30 with no exaggeration of inflammatory
response during the hydrolysis process.31
Although it has been demonstrated, both in vitro and
in vivo, that gelatin-sealing does not increase the thrombo-
genicity of Dacron grafts,29,30 little is known about the
effect of the implantation of a gelatin-impregnated prosthe-
sis on the systemic coagulative and fibrinolytic activity in
patients. The present study showed a similar postoperative
course of molecular markers in patients treated with non-
impregnated Dacron graft and those treated with gelatin-
sealed prosthesis, with no significant difference observed in
any molecular parameters both pre- and postoperatively.
Considering the period of gelatin degradation, the afore-
mentioned results suggest that gelatin-impregnated Da-
cron grafts do not influence the coagulation and fibrinolysis
mechanisms any more than nonimpregnated prostheses.
Soluble FM-fibrinogen complex has been expected to
serve as a risk factor for diverse thrombotic disorders.13-15
In the present study, only one patient had a clinically
symptomatic thrombotic event during the postoperative
course, and we did not perform routine tests postopera-
tively to quantify clinically silent thrombotic events. Con-
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sion on the usefulness of soluble FM-fibrinogen complex as
a potential risk factor for thrombosis. The impact of anti-
coagulant therapy on the plasma level of soluble FM-
fibrinogen complex could not be evaluated either, since
only three patients received anticoagulant therapy during
the study period. Larger studies are necessary in order to
further clarify the clinical value of its measurement.
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